The first generation resulted in exenatide (marketed as Byetta), a synthetic version of exendin-4 approved for clinical use
The economic burden of OSA is substantial, with undiagnosed OSA estimated to cost the United States approximately $149.6 billion in 2015
Signs include difficulty breathing, chest tightness, and dizziness
They may promote lighter skin, smoother texture, and protection from the environment
Long light and short sleep As shift and night work become more common in modern industrial societies, shorter night shift intervals do not provide sufficient recovery time to adjust circadian rhythms, resulting in poor sleep quality (68), prolonged artificial light exposure, and reduced sleep duration (69)